Gamma‑delta T Cells Offer New Hope for Small Cell Lung Cancer

A new study shows that a rare class of immune cells, called gamma‑delta T cells, can recognize and attack small cell lung cancer (SCLC) cells. The researchers examined tumour samples from a dozen patients and found the cells in every sample, suggesting they have the tools to kill the cancer. Small cell lung cancer accounts for about 10–15 % of all lung cancers and grows very quickly, with a five‑year survival rate of less than 7 %.

SCLC is notorious for hiding from the immune system by reducing the production of major histocompatibility complex class I molecules, which are needed for conventional T cells to spot cancer cells. Gamma‑delta T cells work differently; they can detect cellular stress signals, allowing them to find cancers that have evaded other immune cells. Analysis of previous clinical trials showed that patients whose tumours displayed strong gamma‑delta T‑cell signatures survived longer when treated with checkpoint inhibitors during chemotherapy.

In the laboratory, the team tested two drugs that might help gamma‑delta T cells kill SCLC cells. One drug, tarlatamab, links a tumour‑associated protein called DLL3 to the CD3 receptor on T cells, drawing the immune cells closer to the cancer cells. The other, zoledronate, a drug used for bone disease, changes pathways inside the cancer cells, making them more vulnerable to attack by gamma‑delta T cells.

These findings suggest new approaches for immunotherapy. Scientists could expand a patient’s gamma‑delta T cells outside the body and then reintroduce them, a method already being explored for other cancers. Zoledronate might boost the number and activity of the cells, while tarlatamab could guide their attack directly at the tumour. Larger studies with more samples and animal models will be needed to determine which patients benefit and whether survival improves.

The research highlights an often overlooked part of the immune system that could help defeat one of the most stubborn forms of lung cancer. By moving beyond conventional T cells, future therapies might expose weaknesses in SCLC that have long protected the disease from treatment.